SCHEMBL10152040

SCHEMBL10152040

CS(=O)(=O)c1cc(F)c(N)c(F)c1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CA1 P00915 4/20 0.50
CA2 P00918 4/20 0.50
CA9 Q16790 4/20 0.50
CA3 P07451 1/20 0.48
CA12 O43570 1/20 0.42
CA4 P22748 1/20 0.42
CA6 P23280 1/20 0.42
CA5A P35218 1/20 0.42
CA7 P43166 1/20 0.42
CA14 Q9ULX7 1/20 0.42
CA5B Q9Y2D0 1/20 0.42
PTGS2 P35354 8/20 0.41
G6PD P11413 1/20 0.39
IDE P14735 1/20 0.39
KIF11 P52732 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
ADRB2 P07550 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16923275 0.87 CA1 (0.44) CA1CA2CA9CA3CA12
SCHEMBL16909296 0.86 CA1 (0.72) CA1CA2CA9CA3CA12
SCHEMBL1757853 0.86 CA1 (0.70) CA1CA2CA9CA3CA12
SCHEMBL18398423 0.84 CA1 (0.42) CA1CA2CA9CA3CA12
SCHEMBL23144354 0.82 PTGS2 (0.44) CA1CA2CA9CA3PTGS2
SCHEMBL5981674 0.80 CA1 (0.54) CA1CA2CA9CA3CA12
SCHEMBL790517 0.80 PTGS2 (0.44) CA1CA2CA12CA7PTGS2
SCHEMBL1757703 0.80 CA1 (0.39) CA1CA2CA9CA3CA12
SCHEMBL14706960 0.78 PTGS2 (0.46) PTGS2KIF11HDAC1HDAC6
SCHEMBL18230947 0.76 PTGS2 (0.41) CA1CA2CA9PTGS2KIF11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250177396-A1 POLO-LIKE KINASE 4 (PLK4) INHIBITORS, PHARMACEUTICAL COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF REPARE THERAPEUTICS INC. (CA) 2025-06-05 US disclosed
EP-4482833-A1 POLO-LIKE KINASE 4 (PLK4) INHIBITORS, PHARMACEUTICAL COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF Repare Therapeutics Inc. (CA) 2025-01-01 EP disclosed
CN-118946560-A POLO-like kinase 4 (PLK 4) inhibitors, pharmaceutical compositions, methods for their preparation and uses 修复治疗公司 2024-11-12 CN disclosed
WO-2023159307-A9 POLO-LIKE KINASE 4 (PLK4) INHIBITORS, PHARMACEUTICAL COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF REPARE THERAPEUTICS INC. (CA) 2024-03-21 WO disclosed
WO-2023159307-A1 POLO-LIKE KINASE 4 (PLK4) INHIBITORS, PHARMACEUTICAL COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF REPARE THERAPEUTICS INC. (CA) 2023-08-31 WO disclosed
EP-2217596-B1 BICYCLIC HETEROCYCLE DERIVATIVES AND THEIR USE AS MODULATORS OF THE ACTIVITY OF GPR119 MERCK SHARP & DOHME (US) 2013-01-30 EP disclosed
WO-2012037393-A1 PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS ARRAY BIOPHARMA INC. (US) 2012-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250177396-A1 POLO-LIKE KINASE 4 (PLK4) INHIBITORS, PHARMACEUTICAL COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF PLK4, PLK2, PLK3 CA1 4874/4885CA2 4815/4885CA9 4741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.